TAK

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.03
Percentage change -0.22	%

Peers: PFE MRK BMY GSK SNY LLY AZN JNJ NVS ABBV

| Held by: FVD PPH APIE AVDE GINX VEU OZEM PTIN AVSD DFIC

Scroll to Statements

Index	-	P/E	22.26	EPS (ttm)	0.60	Insider Own	0.02%	Shs Outstand	3.17B	Perf Week	-2.26%
Market Cap	42.55B	Forward P/E	30.24	EPS next Y	0.44	Insider Trans	0.00%	Shs Float	3.17B	Perf Month	-1.03%
Income	1.92B	PEG	0.64	EPS next Q	0.09	Inst Own	5.17%	Short Float	0.16%	Perf Quarter	-9.32%
Sales	30.22B	P/S	1.41	EPS this Y	-10.87%	Inst Trans	0.91%	Short Ratio	2.78	Perf Half Y	2.44%
Book/sh	15.26	P/B	0.88	EPS next Y	68.75%	ROA	1.91%	Short Interest	4.92M	Perf Year	-5.16%
Cash/sh	1.89	P/C	7.08	EPS next 5Y	35.03%	ROE	4.02%	52W Range	12.57 - 15.08	Perf YTD	-5.96%
Dividend Est.	0.64 (4.80%)	P/FCF	10.46	EPS past 5Y	-12.87%	ROI	2.42%	52W High	-11.01%	Beta	0.55
Dividend TTM	0.62 (4.61%)	Quick Ratio	0.77	Sales past 5Y	11.56%	Gross Margin	53.44%	52W Low	6.72%	ATR (14)	0.17
Dividend Ex-Date	Sep 30, 2024	Current Ratio	1.28	EPS Y/Y TTM	35.91%	Oper. Margin	13.36%	RSI (14)	41.59	Volatility	1.04% 1.07%
Employees	49281	Debt/Eq	0.73	Sales Y/Y TTM	1.12%	Profit Margin	6.36%	Recom	2.20	Target Price	15.43
Option/Short	Yes / Yes	LT Debt/Eq	0.64	EPS Q/Q	280.49%	Payout	176.43%	Rel Volume	0.62	Prev Close	13.45
Sales Surprise	3.17%	EPS Surprise	53.96%	Sales Q/Q	9.21%	Earnings	Oct 31 AMC	Avg Volume	1.77M	Price	13.42
SMA20	-1.14%	SMA50	-2.93%	SMA200	-2.92%	Trades		Volume	1,096,674	Change	-0.22%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-16-23	Upgrade	BofA Securities	Neutral → Buy	$20
Jul-19-22	Upgrade	Cowen	Market Perform → Outperform	$21 → $24
Oct-07-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-19-21	Downgrade	JP Morgan	Overweight → Neutral
Nov-01-19	Initiated	Cowen	Market Perform	$19.50
Aug-15-19	Downgrade	Daiwa Securities	Outperform → Neutral

Dec-12-24 07:00PM	HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib) (GlobeNewswire)
05:30PM	Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas (Business Wire)
Dec-04-24 06:07AM	Novavax sells Czech plant to Novo; Relay licenses out a cancer drug (BioPharma Dive)
04:31AM	Takeda licensed for anaemia therapy by Keros Therapeutics (Pharmaceutical Technology)
Dec-03-24 12:37PM	Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst (Benzinga)
07:00AM	Loading…
07:00AM	Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics (Business Wire)
07:00AM	Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept (GlobeNewswire)
06:30AM	Takedas Strong FY2024 H1 Boosts Full-Year Outlook (TipRanks)
Nov-30-24 04:29PM	Why Takeda (TAK) Is One of the Most Profitable Pharmaceutical Stocks Right Now? (Insider Monkey)
Nov-29-24 08:08AM	Takeda Canada co-sponsors grant to boost IBD clinical research (Clinical Trials Arena)
Nov-21-24 11:30PM	HUTCHMED Announces Launch by Takeda of FRUZAQLA (fruquintinib) in Japan (GlobeNewswire)
08:22AM	Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies (Pharmaceutical Technology)
Nov-13-24 11:46AM	Why this major drugmaker no longer has an IT department (Fortune)
Nov-07-24 07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire)
Nov-04-24 08:01AM	New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD (PR Newswire)
04:30AM	Loading…
Oct-31-24 04:30AM	HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA (fruquintinib) Sales by Takeda (GlobeNewswire)
02:05AM	Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook (Business Wire)
Oct-30-24 09:00AM	What To Expect From Takeda Pharmaceutical Co Ltd (TSE:4502) Q2 2025 Earnings (GuruFocus.com)
Oct-25-24 07:04AM	Takeda and BMC partner to decarbonise US healthcare sector (Pharmaceutical Technology)
Oct-24-24 08:00AM	Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem (Business Wire)
Oct-23-24 03:05AM	Dengue is spreading and Sanofi is pulling the U.S. markets only vaccine. Whats next? (Pharma Voice)
Oct-22-24 08:54AM	Deko and Shire Leasing partner to offer B2B leasing at checkout (Leasing Life)
Oct-17-24 02:32PM	Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside (Benzinga)
Oct-15-24 07:02PM	Strategic Moves in the Japanese Market: T. Rowe Price Japan Fund's Focus on Takeda Pharmaceutical (GuruFocus.com)
Oct-09-24 05:36PM	WAVE Life Sciences Ltd (WVE) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... (GuruFocus.com)
Oct-03-24 09:40AM	Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now? (Zacks)
Sep-27-24 06:32AM	Tempus AI expands oncology collaboration with Takeda (Pharmaceutical Technology)
Sep-26-24 08:30AM	Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development (Business Wire)
Sep-24-24 06:33AM	Takedas FRUZAQLA approved in Japan for advanced colorectal cancer (Pharmaceutical Technology)
03:00AM	Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer (Business Wire)
03:00AM	Loading…
03:00AM	HUTCHMED Announces Japan Approval for FRUZAQLA (fruquintinib) Received by Takeda (GlobeNewswire)
Sep-23-24 06:32AM	MHRA approves Takedas fruquintinib for metastatic colorectal cancer (Pharmaceutical Technology)
Sep-22-24 03:55AM	Takeda Pharmaceutical Company Limited (TAK): Hedge Funds Are Bullish On This Japanese Stock Now (Insider Monkey)
Sep-19-24 08:00AM	Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024 (Business Wire)
06:33AM	Lupin and Takeda to commercialise Vonoprazan in India (Pharmaceutical Technology)
Sep-18-24 10:00AM	Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries (Business Wire)
Sep-17-24 09:40AM	Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now? (Zacks)
Sep-16-24 08:39AM	Vatroslav Mateljic Appointed General Manager of Takeda Canada (PR Newswire)
Sep-11-24 05:38AM	Buyout Firm GTCR Is in Advanced Talks to Acquire German Drugmaker Stada (Bloomberg)
Sep-10-24 08:15AM	Investors are waking up to Centessas sleepiness drug (BioPharma Dive)
Aug-28-24 12:31PM	Takeda Pharmaceutical Company Limited (TAK): A Cheap Pharmaceutical Stock to Buy According to Short Sellers (Insider Monkey)
Aug-08-24 06:33AM	Takedas ADZYNMA gains EU approval for cTTP treatment (Pharmaceutical Technology)
Aug-07-24 02:29PM	Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday? (Benzinga)
06:45AM	Takeda Receives European Commission Approval for ADZYNMA (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP) (Business Wire)
Aug-05-24 11:32PM	Japan Fund That Beat 92% of Peers in 2024 Touts Seven & I, Orix (Bloomberg)
03:36PM	Japans Selloff Sank Global Markets. Why This Fund Manager Is Still Bullish. (Barrons.com)
Aug-01-24 04:52AM	Takedas revenue climbs by 14.1% in Q1 FY2024 (Pharmaceutical Technology)
Jul-31-24 02:06AM	Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline (Business Wire)
Jul-29-24 06:00AM	3 Biotech Stocks to Buy on the Dip: July 2024 (InvestorPlace)
Jul-15-24 08:55AM	Shire Leasing accredited to deliver Growth Guarantee Scheme (Leasing Life)
Jul-08-24 06:54PM	OPKO Health, Inc. (OPK): Most Shorted Stock Loved by Analysts Right Now? (Insider Monkey)
10:53AM	Polpharma looks to challenge Takedas Entyvio in IBD (Pharmaceutical Technology)
Jul-01-24 11:13AM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace)
Jun-26-24 03:05AM	Takeda Announces New Assignments of Directors (Business Wire)
Jun-24-24 06:32AM	Takeda reports positive data from Phase IIb trial of ITP treatment (Clinical Trials Arena)
04:42AM	EC approves Takedas Fruzaqla for metastatic colorectal cancer (Pharmaceutical Technology)
03:00AM	Takeda Announces Approval of LIVTENCITY (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies (Business Wire)
Jun-22-24 10:30PM	Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia (Business Wire)
Jun-21-24 04:00PM	Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer (Business Wire)
04:00PM	HUTCHMED Announces European Commission Approval for FRUZAQLA (fruquintinib) Received by Takeda (GlobeNewswire)
08:00AM	Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older (PR Newswire)
Jun-19-24 04:52AM	Takeda reports long-term data from Phase III CIDP treatment trial (Clinical Trials Arena)
Jun-18-24 08:00AM	Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting (Business Wire)
Jun-17-24 11:53AM	Takedas epilepsy drug misses the mark in two Phase III trials (Clinical Trials Arena)
08:07AM	Takeda drug for rare types of epilepsy misses goal in late-stage trial (BioPharma Dive)
06:45AM	Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome (Business Wire)
Jun-14-24 12:54PM	Takeda signs option agreement with Ascentage for CML drug (Pharmaceutical Technology)
08:00AM	Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI) (Business Wire)
07:50AM	Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing (BioPharma Dive)
Jun-11-24 08:00AM	Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts (Business Wire)
Jun-06-24 08:15AM	HEALWELL AI's Pentavere Announces Partnership with Takeda to Support Rare Disease Real-World Evidence Analysis for Patients living with Hereditary Angioedema (GlobeNewswire)
06:45AM	7 F-Rated Stocks to Avoid at All Costs in June (InvestorPlace)
Jun-03-24 06:46AM	Takeda, Pfizer report positive Phase III HD21 trial of ADCETRIS (Clinical Trials Arena)
06:46AM	Takeda and Pfizer report positive Phase III HD21 trial of ADCETRIS (Clinical Trials Arena)
06:45AM	Takedas TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo (Business Wire)
04:56AM	Blackstone Is Considering the Sale of Alinamin Pharmaceutical, Sources Say (Bloomberg)
Jun-01-24 08:00AM	Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma (Business Wire)
May-31-24 09:57AM	Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP) (Business Wire)
May-17-24 04:12PM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace)
May-16-24 10:11AM	Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment (MT Newswires)
08:02AM	Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection (PR Newswire)
04:51AM	Takedas dengue vaccine obtains WHO prequalification (Pharmaceutical Technology)
May-15-24 01:52PM	Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification (MT Newswires)
May-14-24 12:23PM	Update: Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute (MT Newswires)
10:01AM	Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute (MT Newswires)
08:00AM	Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting (Business Wire)
May-13-24 11:22AM	Takeda shells out $100m to license AC Immunes Phase II Alzheimers therapy (Pharmaceutical Technology)
08:02AM	Takeda nabs option to license Alzheimers immunotherapies from AC Immune (BioPharma Dive)
07:26AM	Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate (MT Newswires)
06:00AM	AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease (GlobeNewswire)
May-10-24 09:30AM	Catalyst's New CEO Has Big Ideas For The Small Biotech (Investor's Business Daily)
May-09-24 03:46PM	Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50% (Benzinga)
10:03AM	Takeda tackles $900m restructuring plan after generics hurt annual profits (Pharmaceutical Technology)
07:52AM	Takeda targets efficiency in restructuring, pipeline cuts (BioPharma Dive)
06:52AM	TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q4 2023 (InvestorPlace)
04:23AM	Takeda Pharmaceutical's Fiscal Q1 Core Earnings Decline, Revenue Increases; Fiscal 2024 Outlook Issued (MT Newswires)
02:56AM	Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss (The Wall Street Journal)
02:07AM	Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion (Business Wire)
May-08-24 07:51PM	Nikkei Up 0.2%, Led by Banks, Insurers (The Wall Street Journal)
May-07-24 09:04PM	Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations (GuruFocus.com)

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Giles Richard Platford	President, Plasma-Derived Ther	Aug 23 '24	Proposed Sale	14.94	19,073	284,951		Aug 22 08:36 PM
TAKEDA PHARMACEUTICAL CO LTD	10% Owner	Jan 24 '24	Sale	8.10	3,703,703	29,999,994	3,755,583	Jan 25 06:13 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Takeda Pharmaceutical Co ADR

Upgrade your FINVIZ experience